<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01441193</url>
  </required_header>
  <id_info>
    <org_study_id>ISS P-002</org_study_id>
    <nct_id>NCT01441193</nct_id>
  </id_info>
  <brief_title>A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)</brief_title>
  <official_title>A Phase I, Open Label, Safety and Immunogenicity Vaccine Trial Based on the Association of Recombinant HIV-1 Biologically Active Tat and V2-deleted Env Proteins in HIV Uninfected Healthy Adult Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ensoli, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Superiore di Sanità</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I study was directed at evaluating the safety profile and the immunogenicity of
      the vaccination with recombinant HIV-1 Tat and V2-deleted Env (delta-V2 Env) proteins
      administered in association in healthy, immunologically competent adults, compared to
      delta-V2 Env or Tat alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since the inexorable spreading of HIV pandemic is unabated, the urgency of designing an
      effective, safe, inexpensive and easily administrable vaccine to protect people from HIV
      and/or AIDS is an absolute priority. Considering the array of functions sequentially exerted
      by the regulatory and the structural gene products in supporting the setting of a primary HIV
      infection, it is expected that vaccines combining early and late viral products (combined
      vaccines) should be superior to the single antigens approaches since they target multiple
      viral proteins which are necessary at different key steps of the virus life cycle, including
      cell-to-cell virus transmission and systemic virus propagation. A combined vaccine strategy
      based on the early regulatory protein Tat in association with the late structural protein Env
      modified to increase its immunogenicity (delta-V2Env) has been evaluated in pre-clinical
      studies in both small animals and monkeys. The results of these studies indicated that the
      combination of Tat with delta-V2Env is superior in inducing specific immune responses against
      both Tat and delta-V2Env antigens and in protecting or containing virus replication more
      efficiently than vaccination with the single antigens alone, confirming that these proteins
      represent optimal co-antigens for a combined vaccine strategy.

      This study was a multicentric, open label, randomized phase I trial, directed to qualify the
      safety and the immunogenicity of the vaccine based on the association of HIV-1 biologically
      active Tat and oligomeric ΔV2 Env proteins in healthy, immunologically competent adult
      volunteers, compared to the single compounds. Tat and delta-V2 Env proteins either in
      association or as single compounds were administered by a prime-boost regimen, consisting of
      3 intradermal priming doses followed by 2 intramuscular boosting injections. Of note, phase I
      trials have already been successfully conducted with the 2 single components, at the doses
      proposed in this trial, in healthy individuals.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollments were suspended due to delta-V2 Env unavailability, following the
    EMA/CHMP/BWP/534898/2008 guideline, not allowing the use of a retest date
  </why_stopped>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and immunogenicity</measure>
    <time_frame>up to week 68</time_frame>
    <description>To qualify the vaccine candidate as safe and immunogenic by evaluating the number of local and systemic adverse events, including any significant change in hematological/biochemical/coagulation laboratory parameters, and the frequency of anti-Tat and anti-delta-V2 Env humoral and cellular immune responses</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>HIV-1 Tat/delta-V2 Env combined vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tat 7.5 microg and delta-V2 Env 100 microg associated proteins administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at weeks 24 and 36</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-1 delta-V2 Env vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>delta-V2 Env 100 microg administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at week 24 and 36</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-1 Tat vaccine 7.5 microg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tat 7.5 microg administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at week 24 and 36</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-1 Tat vaccine 30 microg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tat 30 microg administered i.d. at week 0, 4 and 8</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HIV-1 Tat/delta-V2 Env combined vaccine</intervention_name>
    <arm_group_label>HIV-1 Tat/delta-V2 Env combined vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HIV-1 delta-V2 Env vaccine</intervention_name>
    <arm_group_label>HIV-1 delta-V2 Env vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HIV-1 Tat vaccine 7.5 microg</intervention_name>
    <arm_group_label>HIV-1 Tat vaccine 7.5 microg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HIV-1 Tat vaccine 30 microg</intervention_name>
    <arm_group_label>HIV-1 Tat vaccine 30 microg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 18 to 55 years;

          2. Negative blood pregnancy test for women of childbearing potential at screening
             evaluation (a urine dipstick test will be repeated just before each vaccination), and
             use of an acceptable mean of contraception by both men and women, since one month
             prior to immunization (only for women) and until at least 6 months after the last
             immunization;

          3. Blood pressure, heart rate and ECG within normal ranges or with mild alterations
             acknowledged as non clinically significant by the site clinician;

          4. Haematological and biochemical parameters within the clinical site normal ranges or
             with mild alterations acknowledged by the site clinician as non clinically
             significant;

          5. Normal urine dipstick with esterase and nitrite;

          6. Normal thyroid function;

          7. Negative for HIV infection and for anti-Tat antibodies;

          8. Good physical and mental health status;

          9. Availability for the planned study duration;

         10. Signed informed consent.

        Exclusion Criteria:

          1. Concomitant neoplastic diseases;

          2. History of malignant neoplastic diseases;

          3. History of encephalopathy, neuropathy or unstable CNS pathology, immunodeficiency,
             autoimmune disease, angina or cardiac arrhythmias, or any other clinically significant
             medical problems;

          4. History of anaphylaxis or serious adverse reactions to vaccines as well as serum IgE
             levels exceeding 1,000 U.I./mL;

          5. History of serious allergic reaction to any substance, requiring hospitalization or
             emergency medical care;

          6. Chest radiography showing evidence of active or acute cardiac or pulmonary disease;

          7. Any unstable cardiovascular disease;

          8. Active syphilis by TPHA and RPR tests [NOTE: If the serology is documented to be a
             false positive or due to an adequately treated infection, the volunteer is eligible];

          9. Active tuberculosis by cutaneous TB diagnostic test [NOTE: Volunteers with a positive
             PPD and a normal chest X-ray showing no evidence of TB and not requiring specific
             therapy are eligible];

         10. Medical or psychiatric condition or occupational responsibilities which preclude
             subject compliance with the protocol. Persons with psychotic disorders, major
             affective disorders or suicidal ideation are specifically excluded;

         11. Current use of psychotropic drugs;

         12. Drug and/or alcohol abuse;

         13. Current or prior therapy with immunomodulators or immunosuppressive drugs and
             anticoagulant drugs within 30 days prior to study medication administration;

         14. Live attenuated vaccines within 60 days prior to study entry [NOTE: Medically
             indicated sub-unit or killed vaccines (e.g, influenza, pneumococcal, hepatitis A and
             B) are not exclusionary, but should be given at least 4 weeks away from anti-HIV
             immunizations];

         15. Use of investigational agents within 90 days prior to study entry;

         16. Participation in another experimental protocol within 6 months prior to pre-study
             screening;

         17. Prior receipt of HIV vaccine in a previous HIV vaccine trial;

         18. Receipt of blood products or immunoglobulin in the past 6 months;

         19. Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Ensoli, MD</last_name>
    <role>Study Director</role>
    <affiliation>Istituto Superiore di Sanità</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Policlinico di Modena, Divisione di Malattie Infettive</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo, Divisione di Malattie Infettive</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IFO - S. Gallicano, Dermatologia Infettiva</name>
      <address>
        <city>Rome</city>
        <zip>00153</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.iss.it/aids</url>
    <description>Click here for the Italian National AIDS Center at the Italian National Institute of Health.</description>
  </link>
  <link>
    <url>http://www.hiv1tat-vaccines.info</url>
    <description>Click here for a description of the efforts by the Italian National AIDS Center at the Italian National Institute of Health to develop preventive and therapeutic HIV vaccines based on the HIV-1 Tat protein</description>
  </link>
  <reference>
    <citation>Ensoli B, Bellino S, Tripiciano A, Longo O, Francavilla V, Marcotullio S, Cafaro A, Picconi O, Paniccia G, Scoglio A, Arancio A, Ariola C, Ruiz Alvarez MJ, Campagna M, Scaramuzzi D, Iori C, Esposito R, Mussini C, Ghinelli F, Sighinolfi L, Palamara G, Latini A, Angarano G, Ladisa N, Soscia F, Mercurio VS, Lazzarin A, Tambussi G, Visintini R, Mazzotta F, Di Pietro M, Galli M, Rusconi S, Carosi G, Torti C, Di Perri G, Bonora S, Ensoli F, Garaci E. Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One. 2010 Nov 11;5(11):e13540. doi: 10.1371/journal.pone.0013540.</citation>
    <PMID>21085635</PMID>
  </reference>
  <reference>
    <citation>Bellino S, Francavilla V, Longo O, Tripiciano A, Paniccia G, Arancio A, Fiorelli V, Scoglio A, Collacchi B, Campagna M, Lazzarin A, Tambussi G, Din CT, Visintini R, Narciso P, Antinori A, D'Offizi G, Giulianelli M, Carta M, Di Carlo A, Palamara G, Giuliani M, Laguardia ME, Monini P, Magnani M, Ensoli F, Ensoli B. Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. Rev Recent Clin Trials. 2009 Sep;4(3):195-204. Review.</citation>
    <PMID>20028332</PMID>
  </reference>
  <reference>
    <citation>Ensoli B, Fiorelli V, Ensoli F, Lazzarin A, Visintini R, Narciso P, Di Carlo A, Tripiciano A, Longo O, Bellino S, Francavilla V, Paniccia G, Arancio A, Scoglio A, Collacchi B, Ruiz Alvarez MJ, Tambussi G, Tassan Din C, Palamara G, Latini A, Antinori A, D'Offizi G, Giuliani M, Giulianelli M, Carta M, Monini P, Magnani M, Garaci E. The preventive phase I trial with the HIV-1 Tat-based vaccine. Vaccine. 2009 Dec 11;28(2):371-8. doi: 10.1016/j.vaccine.2009.10.038. Epub 2009 Oct 29.</citation>
    <PMID>19879233</PMID>
  </reference>
  <reference>
    <citation>Caputo A, Gavioli R, Bellino S, Longo O, Tripiciano A, Francavilla V, Sgadari C, Paniccia G, Titti F, Cafaro A, Ferrantelli F, Monini P, Ensoli F, Ensoli B. HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development. Int Rev Immunol. 2009;28(5):285-334. doi: 10.1080/08830180903013026. Review.</citation>
    <PMID>19811313</PMID>
  </reference>
  <reference>
    <citation>Longo O, Tripiciano A, Fiorelli V, Bellino S, Scoglio A, Collacchi B, Alvarez MJ, Francavilla V, Arancio A, Paniccia G, Lazzarin A, Tambussi G, Din CT, Visintini R, Narciso P, Antinori A, D'Offizi G, Giulianelli M, Carta M, Di Carlo A, Palamara G, Giuliani M, Laguardia ME, Monini P, Magnani M, Ensoli F, Ensoli B. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine. 2009 May 26;27(25-26):3306-12. doi: 10.1016/j.vaccine.2009.01.090. Epub 2009 Feb 7.</citation>
    <PMID>19208456</PMID>
  </reference>
  <reference>
    <citation>Ensoli B, Fiorelli V, Ensoli F, Cafaro A, Titti F, Buttò S, Monini P, Magnani M, Caputo A, Garaci E. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. AIDS. 2006 Nov 28;20(18):2245-61. Review.</citation>
    <PMID>17117011</PMID>
  </reference>
  <reference>
    <citation>Barnett SW, Srivastava IK, Ulmer JB, Donnelly JJ, Rappuoli R. Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C. Microbes Infect. 2005 Nov;7(14):1386-91. Epub 2005 Sep 20.</citation>
    <PMID>16275150</PMID>
  </reference>
  <reference>
    <citation>Ensoli B, Cafaro A, Caputo A, Fiorelli V, Ensoli F, Gavioli R, Ferrantelli F, Cara A, Titti F, Magnani M. Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env. Microbes Infect. 2005 Nov;7(14):1392-9. Epub 2005 Sep 15.</citation>
    <PMID>16243561</PMID>
  </reference>
  <reference>
    <citation>Caputo A, Brocca-Cofano E, Castaldello A, Voltan R, Gavioli R, Srivastava IK, Barnett SW, Cafaro A, Ensoli B. Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin. Vaccine. 2008 Feb 26;26(9):1214-27. doi: 10.1016/j.vaccine.2007.12.030. Epub 2008 Jan 15.</citation>
    <PMID>18243435</PMID>
  </reference>
  <reference>
    <citation>Bellino S, Tripiciano A, Picconi O, Francavilla V, Longo O, Sgadari C, Paniccia G, Arancio A, Angarano G, Ladisa N, Lazzarin A, Tambussi G, Nozza S, Torti C, Focà E, Palamara G, Latini A, Sighinolfi L, Mazzotta F, Di Pietro M, Di Perri G, Bonora S, Mercurio VS, Mussini C, Gori A, Galli M, Monini P, Cafaro A, Ensoli F, Ensoli B. The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. Retrovirology. 2014 Jun 24;11:49. doi: 10.1186/1742-4690-11-49.</citation>
    <PMID>24961156</PMID>
  </reference>
  <reference>
    <citation>Ensoli B, Cafaro A, Monini P, Marcotullio S, Ensoli F. Challenges in HIV Vaccine Research for Treatment and Prevention. Front Immunol. 2014 Sep 8;5:417. doi: 10.3389/fimmu.2014.00417. eCollection 2014. Review.</citation>
    <PMID>25250026</PMID>
  </reference>
  <reference>
    <citation>Ensoli F, Cafaro A, Casabianca A, Tripiciano A, Bellino S, Longo O, Francavilla V, Picconi O, Sgadari C, Moretti S, Cossut MR, Arancio A, Orlandi C, Sernicola L, Maggiorella MT, Paniccia G, Mussini C, Lazzarin A, Sighinolfi L, Palamara G, Gori A, Angarano G, Di Pietro M, Galli M, Mercurio VS, Castelli F, Di Perri G, Monini P, Magnani M, Garaci E, Ensoli B. HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. Retrovirology. 2015 Apr 29;12:33. doi: 10.1186/s12977-015-0151-y.</citation>
    <PMID>25924841</PMID>
  </reference>
  <reference>
    <citation>Cafaro A, Tripiciano A, Sgadari C, Bellino S, Picconi O, Longo O, Francavilla V, Buttò S, Titti F, Monini P, Ensoli F, Ensoli B. Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine. Expert Opin Biol Ther. 2015;15 Suppl 1:S13-29. doi: 10.1517/14712598.2015.1021328. Epub 2015 Jun 22. Review.</citation>
    <PMID>26096836</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2011</study_first_submitted>
  <study_first_submitted_qc>September 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2011</study_first_posted>
  <last_update_submitted>March 3, 2016</last_update_submitted>
  <last_update_submitted_qc>March 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Superiore di Sanità</investigator_affiliation>
    <investigator_full_name>Barbara Ensoli, MD</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>preventive vaccine</keyword>
  <keyword>Tat</keyword>
  <keyword>Env</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

